// App-Quantinova.ai

3900 : Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14

Researchers

Presenter

  • Bella Patel

Principal Investigators

  • A Kirkwood

  • Aditi Dey

  • Clare Rowntree

  • Andrew McMillan

  • David Marks

  • Tobias Menne

  • Paul Smith

  • Simon Purnell

  • Lynda Micklewright

  • Adele K Fielding

Medical Centers

  • Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

  • Academic Department of Haematology, Hampstead Campus, University College London, London, United Kingdom

  • CRUK and UCL Cancer Trials Centre, London, United Kingdom

  • Cardiff and Vale UHB, London, United Kingdom

  • United Bristol Healthcare Trust., Bristol, United Kingdom

  • Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Acute Coronary Syndromes

  • Pancreatitis

  • Venous thrombosis

  • Sepsis

Biomarkers

  • Breakpoint Cluster Region

  • Ph chromosome

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Allmercap

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Daunorubicin

  • Methotrexate

  • Asparaginase

  • Vincristine

  • Rituximab

  • Imatinib

  • IkT001

  • ara-c

  • Mofezolac

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved